Research programme: infectious disease vaccines - Lumos Pharma
Alternative Names: Alpha-Gal influenza virus vaccines; Influenza virus vaccine - Lumos Pharma; Zika virus vaccine - Lumos PharmaLatest Information Update: 28 Mar 2020
At a glance
- Originator NewLink Genetics Corporation
- Developer Lumos Pharma
- Class Influenza virus vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections; Zika virus infection
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral)
- 02 Feb 2016 Early research in Zika virus infection in USA (Parenteral)
Development Overview
Introduction
Lumos Pharma (previously NewLink Genetics) is developing vaccines based on the its proprietary HyperAcute® vaccine technology, which involves α(1,3)-galactosyltransferase (αGal) gene modification of vaccines, including virus-like particle vaccines and recombinant vaccines. The αGal gene codes for an enzyme that adds certain sugars to proteins and lipids in the cell membranes of lower mammals. Humans do not express these sugar moieties and therefore develop a strong immunological response to cells expressing these modifications. αGal-modification of vaccines enhances immune responses without the use of an adjuvant. NewLink Genetics has investigated the feasibility of αGal of various influenza vaccines, but the company has stated that the HyperAcute® vaccine technology is not limited to influenza vaccines. Preclinical development is underway in the US.
Lumos Pharma is also developing a Zika vaccine candidate for the treatment of Zirus virus infections [1] .
As at August 2018, no recent reports of development had been identified for preclinical development in Influenza-virus-infections (Prevention) in USA (Parenteral).
As at March 2020, no recent reports of development had been identified for research development in Zika-virus-infection in USA (Parenteral).
In March 2020, NewLink Genetics Corporation and Lumos Pharma merged to form Lumos Pharma [2] .
Key Development Milestones
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Influenza virus vaccines, Viral vaccines, Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-B (Influenza vaccines)
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
J7E1 (Influenza vaccines)
Development Status
Summary Table
Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
---|---|---|---|---|---|---|---|
Influenza virus infections | - | Prevention | No development reported (Preclinical) | USA | Parenteral / unspecified | Lumos Pharma | 28 Aug 2018 |
Zika virus infection | - | - | No development reported (Research) | USA | Parenteral / unspecified | Lumos Pharma | 28 Mar 2020 |
Commercial Information
Involved Organisations
Organisation | Involvement | Countries |
---|---|---|
NewLink Genetics Corporation | Originator | USA |
Lumos Pharma | Owner | USA |
Development History
Event Date | Update Type | Comment |
---|---|---|
28 Mar 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral) Updated 28 Mar 2020 |
18 Mar 2020 | Company Involvement | NewLink Genetics Corporation has merged with Lumos Pharma to form Lumos Pharma Updated 21 May 2020 |
28 Aug 2018 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral) Updated 28 Aug 2018 |
02 Feb 2016 | Phase Change | Early research in Zika virus infection in USA (Parenteral) Updated 05 Feb 2016 |
27 Aug 2014 | Phase Change - Preclinical | Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral) Updated 27 Aug 2014 |
References
-
NewLink Genetics Corporation Announces Project to Develop New Treatment Options for the Zika Virus.
Media Release -
NewLink Genetics Stockholders Approve Merger with Lumos Pharma.
Media Release -
NewLink Genetics to Present at the XVIth International Congress of Virology.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG